{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T17:02:56Z","timestamp":1775149376000,"version":"3.50.1"},"reference-count":42,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Mirikizumab is a monoclonal antibody directed against the p19 subunit of interleukin (IL)-23 to inhibit its interaction with the IL-23 receptor. IL-23 is a key cytokine involved in initiating and perpetuating the inflammatory cascade in inflammatory bowel disease (IBD). Mirikizumab is the first agent from the novel anti-IL-23p19 drug class to be licensed for ulcerative colitis and the first to present long-term endoscopic, histologic, symptomatic, and quality-of-life outcomes. More recently, the VIVID trial programme has led to the approval of mirikizumab in moderate to severe Crohn\u2019s disease. This review explores the history of its development, discusses key immunopharmacological properties unique to the drug, and details the available clinical trials and real-world evidence supporting its use in IBD.<\/jats:p>","DOI":"10.3390\/jcm14031001","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T04:15:41Z","timestamp":1738728941000},"page":"1001","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Role of Mirikizumab in the Treatment of Inflammatory Bowel Disease\u2014From Bench to Bedside"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6925-8358","authenticated-orcid":false,"given":"Michael","family":"Colwill","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, St George\u2019s University Hospital NHS Foundation Trust, London SW17 0QT, UK"},{"name":"Institute of Infection and Immunity, City St George\u2019s, University of London, London SW17 0RE, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3280-0347","authenticated-orcid":false,"given":"Samantha","family":"Baillie","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, St George\u2019s University Hospital NHS Foundation Trust, London SW17 0QT, UK"},{"name":"Institute of Infection and Immunity, City St George\u2019s, University of London, London SW17 0RE, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Clough","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, St George\u2019s University Hospital NHS Foundation Trust, London SW17 0QT, UK"},{"name":"School of Immunology and Microbial Sciences, King\u2019s College London, London WC2R 2LS, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6452-6763","authenticated-orcid":false,"given":"Richard","family":"Pollok","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, St George\u2019s University Hospital NHS Foundation Trust, London SW17 0QT, UK"},{"name":"Institute of Infection and Immunity, City St George\u2019s, University of London, London SW17 0RE, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Poullis","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, St George\u2019s University Hospital NHS Foundation Trust, London SW17 0QT, UK"},{"name":"Institute of Infection and Immunity, City St George\u2019s, University of London, London SW17 0RE, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamal","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, St George\u2019s University Hospital NHS Foundation Trust, London SW17 0QT, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6657-2763","authenticated-orcid":false,"given":"Sailish","family":"Honap","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, St George\u2019s University Hospital NHS Foundation Trust, London SW17 0QT, UK"},{"name":"School of Immunology and Microbial Sciences, King\u2019s College London, London WC2R 2LS, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0016-5085(95)90277-5","article-title":"Treatment of Crohn\u2019s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)","volume":"109","author":"Hommes","year":"1995","journal-title":"Gastroenterology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_3","first-page":"375","article-title":"The Overview of the Immunobiology of Interleukin-23 Associated With Immune-Mediated Inflammatory Disorders: A Narrative Review","volume":"22","author":"Sanchez","year":"2023","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Krueger, J.G., Eyerich, K., Kuchroo, V.K., Ritchlin, C.T., Abreu, M.T., Elloso, M.M., Fourie, A., Fakharzadeh, S., Sherlock, J.P., and Yang, Y.W. (2024). IL-23 past, present, and future: A roadmap to advancing IL-23 science and therapy. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1331217"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2567.2011.03522.x","article-title":"Interleukin-23: As a drug target for autoimmune inflammatory diseases","volume":"135","author":"Tang","year":"2012","journal-title":"Immunology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as Induction and Maintenance Therapy for Crohn\u2019s Disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1056\/NEJMoa2207940","article-title":"Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"388","author":"Dubinsky","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7563","DOI":"10.4049\/jimmunol.166.12.7563","article-title":"Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death","volume":"166","author":"Wiekowski","year":"2001","journal-title":"J. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/eji.201242598","article-title":"IL-23: One cytokine in control of autoimmunity","volume":"42","author":"Croxford","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1126\/science.1135245","article-title":"A genome-wide association study identifies IL23R as an inflammatory bowel disease gene","volume":"314","author":"Duerr","year":"2006","journal-title":"Science"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1136\/gut.2011.238477","article-title":"Genetic polymorphisms of IL-23R and IL-17A and novel insights into their associations with inflammatory bowel disease","volume":"60","author":"Kim","year":"2011","journal-title":"Gut"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s10067-013-2469-y","article-title":"Involvement of IL-23 in enteropathic arthritis patients with inflammatory bowel disease: Preliminary results","volume":"33","author":"Gheita","year":"2014","journal-title":"Clin. Rheumatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1097\/MIB.0000000000000210","article-title":"Comprehensive intestinal T helper cell profiling reveals specific accumulation of IFN-\u03b3+IL-17+coproducing CD4+ T cells in active inflammatory bowel disease","volume":"20","author":"Globig","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2018.12.002","article-title":"IL-23 in inflammatory bowel diseases and colon cancer","volume":"45","author":"Neurath","year":"2019","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in Plaque Psoriasis\u2014Results of Two Phase 3 Trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: Unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn\u2019s Disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.immuni.2015.08.019","article-title":"Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation","volume":"43","author":"Maxwell","year":"2015","journal-title":"Immunity"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1124\/jpet.122.001512","article-title":"Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23","volume":"387","author":"Steere","year":"2023","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.4049\/jimmunol.168.11.5699","article-title":"A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R","volume":"168","author":"Parham","year":"2002","journal-title":"J. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1359-6446(02)02590-4","article-title":"Optimization of protein therapeutics by directed evolution","volume":"8","author":"Vasserot","year":"2003","journal-title":"Drug Discov. Today"},{"key":"ref_26","unstructured":"(2024, December 04). OMVOH (Mirikizumab-Mrkz) Injection, for Intravenous or Subcutaneous Use [Internet], Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761279s000lbl.pdf."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1111\/apt.16609","article-title":"Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn\u2019s disease and ulcerative colitis","volume":"54","author":"Hanzel","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Aguiar Zdovc, J., Han\u017eel, J., Kurent, T., Sever, N., Ko\u017eelj, M., Smrekar, N., Novak, G., \u0160tabuc, B., Dreesen, E., and Thomas, D. (2021). Ustekinumab Dosing Individualization in Crohn\u2019s Disease Guided by a Population Pharmacokinetic-Pharmacodynamic Model. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13101587"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2217\/imt-2023-0012","article-title":"Mirikizumab for the treatment of moderate to severe ulcerative colitis","volume":"15","author":"Hanzel","year":"2023","journal-title":"Immunotherapy"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Sands, B.E., D\u2019Haens, G., Clemow, D.B., Irving, P.M., Johns, J.T., Gibble, T.H., Abreu, M.T., Lee, S.D., Hisamatsu, T., and Kobayashi, T. (Inflamm. Bowel Dis., 2024). Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study, Inflamm. Bowel Dis., online ahead of print.","DOI":"10.1093\/ibd\/izae253"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","article-title":"Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn\u2019s disease: A phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study","volume":"404","author":"Ferrante","year":"2024","journal-title":"Lancet"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"i308","DOI":"10.1093\/ecco-jcc\/jjad212.0176","article-title":"P046 Real-world data on the treatment with Mirikizumab in a mostly biological-experienced Ulcerative colitis cohort","volume":"18","author":"Lande","year":"2024","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"317","DOI":"10.14309\/ajg.0000000000002047","article-title":"The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn\u2019s Disease: Results From the SUCCESS Consortium","volume":"118","author":"Johnson","year":"2023","journal-title":"Am. J. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"ii16","DOI":"10.1093\/ecco-jcc\/jjae048","article-title":"Navigating Reproductive Care in Patients With Inflammatory Bowel Disease: A Comprehensive Review","volume":"18","author":"Sousa","year":"2024","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.repbre.2023.10.003","article-title":"A regression approach for assessing large molecular drug concentration in breast milk","volume":"3","author":"Stratigakis","year":"2023","journal-title":"Reprod. Breed."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1016\/S0264-410X(03)00336-0","article-title":"Transfer of antibody via mother\u2019s milk","volume":"21","year":"2003","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"i27","DOI":"10.1093\/ecco-jcc\/jjad212.0014","article-title":"OP14 Effect of mirikizumab on clinical and endoscopic outcomes after 1 anti-TNF failure in patients with moderately to severely active Ulcerative Colitis","volume":"18","author":"Hart","year":"2024","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"S256","DOI":"10.1093\/ecco-jcc\/jjy222.436","article-title":"P312 Efficacy in biologic failure and non-biologic-failure populations in a Phase 3 study of ustekinumab in moderate\u2013severe ulcerative colitis: UNIFI","volume":"13","author":"Sands","year":"2019","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4446","DOI":"10.1007\/s12325-024-03003-8","article-title":"Efficacy and Safety of Advanced Therapies in Moderately-to-Severely Active Ulcerative Colitis: A Systematic Review and Network Meta-analysis","volume":"41","author":"Dignass","year":"2024","journal-title":"Adv. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1053\/j.gastro.2024.07.046","article-title":"Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis","volume":"167","author":"Ananthakrishnan","year":"2024","journal-title":"Gastroenterology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cgh.2023.12.023","article-title":"Comparative Efficacy of Advanced Therapies for Achieving Endoscopic Outcomes in Crohn\u2019s Disease: A Systematic Review and Network Meta-Analysis","volume":"22","author":"Vuyyuru","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S740","DOI":"10.14309\/01.ajg.0001033576.85427.3d","article-title":"S1052 Efficacy and Safety of Subcutaneous Guselkumab Induction Therapy in Patients With Moderately to Severely Active Crohn\u2019s Disease: Results Through Week 48 From the Phase 3 GRAVITI Study","volume":"119","author":"Panaccione","year":"2024","journal-title":"Am. J. Gastroenterol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/3\/1001\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:26:58Z","timestamp":1760027218000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/3\/1001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,5]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["jcm14031001"],"URL":"https:\/\/doi.org\/10.3390\/jcm14031001","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,5]]}}}